Literature DB >> 17417990

Erosive arthropathy: clinical variance in lupus erythematosus and association with anti-CCP case series and review of the literature.

J B Martinez1, J S Valero, A J Bautista, J F Restrepo, E L Matteson, F Rondon, A Iglesias-Gamarra.   

Abstract

OBJECTIVE: To describe the occurrence of erosive arthropathy in systemic lupus erythematosus (SLE) and its relationship to anti-CCP antibodies.
METHODS: Retrospective medical record review of a case series of five female patients with SLE and erosive arthropathies.
RESULTS: The initial disease presentation in all patients was a polyarthritis. Anti-CCP antibodies were detected in 4 out of 5 (80%) patients, 2 of whom had a positive rheumatoid factor.
CONCLUSION: Erosive arthritis was strongly associated with the presence of anti-CCP antibodies in these patients with SLE, who presented with polyarthritis. Anti-CCP in patients with SLE may be a marker of a more severe joint disease.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17417990

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN: 0392-856X            Impact factor:   4.473


  9 in total

1.  Citrulline dependence of anti-cyclic citrullinated peptide antibodies in systemic lupus erythematosus as a marker of deforming/erosive arthritis.

Authors:  Prasanthi Kakumanu; Eric S Sobel; Sonali Narain; Yi Li; Jun Akaogi; Yoshioki Yamasaki; Mark S Segal; Paulette C Hahn; Edward K L Chan; Westley H Reeves; Minoru Satoh
Journal:  J Rheumatol       Date:  2009-11-02       Impact factor: 4.666

2.  Anticyclic citrullinated peptide autoantibodies in systemic lupus erythematosus.

Authors:  Usha Singh; Sangeeta Singh; Nand K Singh; Pramod K Verma; Suman Singh
Journal:  Rheumatol Int       Date:  2010-02-21       Impact factor: 2.631

3.  Anti-CCP in systemic lupus erythematosus patients: a cross sectional study in Brazilian patients.

Authors:  Thelma L Skare; Renato Nisihara; Bruno Bandolin Barbosa; Alvaro da Luz; Shirley Utiyama; Vanessa Picceli
Journal:  Clin Rheumatol       Date:  2013-02-15       Impact factor: 2.980

4.  Lupus IgG deposition causes arthritis but inhibits bone destruction through competitive occupation of FcγRI and reduced RANKL signalling.

Authors:  Wei Qiao; Huimin Ding; Yuyue Zuo; Lijuan Jiang; Jiayuan Zhou; Xiaoxiao Han; Likai Yu; Rong Du; Christian M Hedrich; Guo-Min Deng
Journal:  Clin Transl Immunology       Date:  2020-09-06

5.  A comparative study of IgG second- and third-generation anti-cyclic citrullinated peptide (CCP) ELISAs and their combination with IgA third-generation CCP ELISA for the diagnosis of rheumatoid arthritis.

Authors:  Lisiane Maria Enriconi dos Anjos; Ivanio Alves Pereira; Eleonora d 'Orsi; Andrea Piette Seaman; Rufus Watson Burlingame; Edelton Flavio Morato
Journal:  Clin Rheumatol       Date:  2008-09-16       Impact factor: 2.980

6.  Diagnostic value of synovial fluid anti-cyclic citrullinated peptide antibody for rheumatoid arthritis.

Authors:  Behzad Heidari; Hassan Abedi; Alireza Firouzjahi; Parnaz Heidari
Journal:  Rheumatol Int       Date:  2009-10-13       Impact factor: 2.631

7.  Anti-cyclic citrullinated peptide antibodies in ulcerative colitis, and its relation with disease activity.

Authors:  Afshin Shafaghi; Fariborz Mansour-Ghanaei; Maryam Rostamnejad; Alireza Amir Maafi; Asghar Haji-Abbasi; Hossein Froutan
Journal:  Med J Islam Repub Iran       Date:  2014-07-22

8.  The prevalence and diagnostic performance of anti-cyclic citrullinated peptide antibody in rheumatoid arthritis: the predictive and discriminative ability of serum antibody level in recognizing rheumatoid arthritis.

Authors:  Behzad Heidari; Alireza Firouzjahi; Parnaz Heidari; Karim Hajian
Journal:  Ann Saudi Med       Date:  2009 Nov-Dec       Impact factor: 1.526

Review 9.  An Overview of the Intrinsic Role of Citrullination in Autoimmune Disorders.

Authors:  Mohammed Alghamdi; Doaa Alasmari; Amjad Assiri; Ehab Mattar; Abdullah A Aljaddawi; Sana G Alattas; Elrashdy M Redwan
Journal:  J Immunol Res       Date:  2019-11-25       Impact factor: 4.818

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.